- Home
- RGC vs IQV Comparison
RGC vs IQV Comparison
Compare RGC & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- IQV
- Stock Information
- Founded
- RGC 2014
- IQV 1982
- Country
- RGC Hong Kong
- IQV United States
- Employees
- RGC N/A
- IQV N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RGC Health Care
- IQV Health Care
- Exchange
- RGC Nasdaq
- IQV Nasdaq
- Market Cap
- RGC 38.6B
- IQV 31.0B
- IPO Year
- RGC 2021
- IQV 2013
- Fundamental
- Price
- RGC $13.46
- IQV $183.92
- Analyst Decision
- RGC
- IQV Strong Buy
- Analyst Count
- RGC 0
- IQV 19
- Target Price
- RGC N/A
- IQV $229.37
- AVG Volume (30 Days)
- RGC 780.3K
- IQV 2.3M
- Earning Date
- RGC 06-30-2025
- IQV 07-22-2025
- Dividend Yield
- RGC N/A
- IQV N/A
- EPS Growth
- RGC N/A
- IQV N/A
- EPS
- RGC N/A
- IQV 6.92
- Revenue
- RGC N/A
- IQV $15,700,000,000.00
- Revenue This Year
- RGC N/A
- IQV $6.03
- Revenue Next Year
- RGC N/A
- IQV $5.03
- P/E Ratio
- RGC N/A
- IQV $26.33
- Revenue Growth
- RGC N/A
- IQV 3.60
- 52 Week Low
- RGC $0.09
- IQV $134.65
- 52 Week High
- RGC $83.60
- IQV $252.88
- Technical
- Relative Strength Index (RSI)
- RGC 44.79
- IQV 58.39
- Support Level
- RGC $12.76
- IQV $178.92
- Resistance Level
- RGC $13.77
- IQV $184.62
- Average True Range (ATR)
- RGC 1.35
- IQV 6.76
- MACD
- RGC 0.08
- IQV -0.62
- Stochastic Oscillator
- RGC 12.40
- IQV 53.35
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.